CNBC's Angelica Peebles talks to Structure Therapeutics CEO Ray Stevens about the obesity landscape and why there's still ...

A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the ...

Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.

The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for subcutaneous (SC) maintenance dosing of lecanemab-irmb for the treatment of Alzheimer disease (AD) in ...

In a mouse study, researchers found that zolpidem (Ambien), a common sleep aid, could prevent the brain from effectively ...

"Our study results forecast a dramatic rise in the burden from dementia in the United States over the coming decades, with ...

Greg Lipschitz, Executive Chairman of Firefly, said, “This breakthrough underscores our commitment to pushing the boundaries of innovation in brain health, ultimately with the aim of making a ...

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has accepted BioArctic's partner Eisai's Biologics License Application (BLA) for Leqembi ...

Dementia cases are expected to more than double in the coming decades, with the risk beginning as early as 55, and the ...

New research suggests that the risk for developing dementia is significantly higher than previously estimated, and the burden on the United States population will grow substantially over the next few ...

A predictive tool for determining the age at which individuals may develop mild cognitive impairment (MCI) or Alzheimer's ...

(OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, fibrosis, stroke, dementia, and Alzheimer's disease, announced its ...